181 related articles for article (PubMed ID: 33115981)
1.
Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
[No Abstract] [Full Text] [Related]
2. Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence.
Lee JY; Lee JW; Park TG; Han SH; Yoo SY; Jung KM; Kim DM; Lee OJ; Kim D; Chi XZ; Kim EG; Lee YS; Bae SC
Cells; 2023 Oct; 12(20):. PubMed ID: 37887282
[TBL] [Abstract][Full Text] [Related]
3. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.
Lee YS; Lee JW; Jang JW; Chi XZ; Kim JH; Li YH; Kim MK; Kim DM; Choi BS; Kim EG; Chung JH; Lee OJ; Lee YM; Suh JW; Chuang LS; Ito Y; Bae SC
Cancer Cell; 2013 Nov; 24(5):603-16. PubMed ID: 24229708
[TBL] [Abstract][Full Text] [Related]
4. Role of RUNX3 in Restriction Point Regulation.
Lee JW; Lee YS; Kim MK; Chi XZ; Kim D; Bae SC
Cells; 2023 Feb; 12(5):. PubMed ID: 36899846
[TBL] [Abstract][Full Text] [Related]
5. Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer.
Lee KS; Lee YS; Lee JM; Ito K; Cinghu S; Kim JH; Jang JW; Li YH; Goh YM; Chi XZ; Wee H; Lee HW; Hosoya A; Chung JH; Jang JJ; Kundu JK; Surh YJ; Kim WJ; Ito Y; Jung HS; Bae SC
Oncogene; 2010 Jun; 29(23):3349-61. PubMed ID: 20228843
[TBL] [Abstract][Full Text] [Related]
6. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
[TBL] [Abstract][Full Text] [Related]
7. RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.
Omar MF; Ito K; Nga ME; Soo R; Peh BK; Ismail TM; Thakkar B; Soong R; Ito Y; Salto-Tellez M
Pathol Oncol Res; 2012 Oct; 18(4):783-92. PubMed ID: 22729835
[TBL] [Abstract][Full Text] [Related]
8. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
Duan W; Gao L; Kalvala A; Aguila B; Brooks C; Mo X; Ding H; Shilo K; Otterson GA; Villalona-Calero MA
Int J Cancer; 2019 Nov; 145(9):2418-2426. PubMed ID: 30873587
[TBL] [Abstract][Full Text] [Related]
9. How do K-RAS-activated cells evade cellular defense mechanisms?
Lee YS; Bae SC
Oncogene; 2016 Feb; 35(7):827-32. PubMed ID: 25961920
[TBL] [Abstract][Full Text] [Related]
10. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
Lee JW; van Wijnen A; Bae SC
Adv Exp Med Biol; 2017; 962():321-332. PubMed ID: 28299666
[TBL] [Abstract][Full Text] [Related]
11. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
13. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53.
Yamada C; Ozaki T; Ando K; Suenaga Y; Inoue K; Ito Y; Okoshi R; Kageyama H; Kimura H; Miyazaki M; Nakagawara A
J Biol Chem; 2010 May; 285(22):16693-703. PubMed ID: 20353948
[TBL] [Abstract][Full Text] [Related]
14. Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.
Weyandt JD; Carney JM; Pavlisko EN; Xu M; Counter CM
PLoS One; 2016; 11(12):e0167205. PubMed ID: 27911940
[TBL] [Abstract][Full Text] [Related]
15. miR-301a promotes lung tumorigenesis by suppressing Runx3.
Li X; Zhong M; Wang J; Wang L; Lin Z; Cao Z; Huang Z; Zhang F; Li Y; Liu M; Ma X
Mol Cancer; 2019 May; 18(1):99. PubMed ID: 31122259
[TBL] [Abstract][Full Text] [Related]
16. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
[TBL] [Abstract][Full Text] [Related]
17. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
19. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
[TBL] [Abstract][Full Text] [Related]
20. Sirt1 protects from K-Ras-driven lung carcinogenesis.
Costa-Machado LF; Martín-Hernández R; Sanchez-Luengo MÁ; Hess K; Vales-Villamarin C; Barradas M; Lynch C; de la Nava D; Diaz-Ruiz A; de Cabo R; Cañamero M; Martinez L; Sanchez-Carbayo M; Herranz D; Serrano M; Fernandez-Marcos PJ
EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30021836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
